Semi-physiological pharmacokinetic–pharmacodynamic (PK–PD) modeling and simulation of 5-fluorouracil for thrombocytopenia in rats

References

• Abbott BD, Lau C, Buckalew AR, et al. (1993). Effects of 5-fluorouracil on embryonic rat palate in vitro: fusion in the absence of proliferation. Teratology 47:541–54
   PubMedGoogle Scholar
• Akaike H. (1974). A new look at the statistical model identification. IEEE Trans Automat Control 19:716–18
   Web of Science ®Google Scholar
• Bender BC, Schaedeli-Stark F, Koch R, et al. (2012). A population pharmacokinetic/pharmacodynamic model of thrombocytopenia characterizing the effect of trastuzumab emtansine (T-DM1) on platelet counts in patients with HER2-positive metastatic breast cancer. Cancer Chemother Pharmacol 70:591–601
   PubMed Web of Science ®Google Scholar
• Capitain O, Asevoaia A, Boisdron-Celle M, et al. (2012). Individual fluorouracil dose adjustment in FOLFOX based on pharmacokinetic follow-up compared with conventional body-area-surface dosing: a phase II, proof-of-concept study. Clin Colorectal Cancer 11:263–7
   PubMed Web of Science ®Google Scholar
• Chalret du Rieu Q, Fouliard S, Jacquet-Bescond A, et al. (2013). Application of hematological toxicity modeling in clinical development of abexinostat (S-78454, PCI-24781), a new histone deacetylase inhibitor. Pharm Res 30:2640–53
   Google Scholar
• Friberg LE, Freijs A, Sandstrom M, et al. (2000). Semiphysiological model for the time course of leukocytes after varying schedules of 5-fluorouracil in rats. J Pharmacol Exp Ther 295:734–40
   PubMed Web of Science ®Google Scholar
• Friberg LE, Henningsson A, Maas H, et al. (2002). Model of chemotherapy-induced myelosuppression with parameter consistency across drugs. J Clin Oncol 20:4713–21
   PubMed Web of Science ®Google Scholar
• Gamelin E, Delva R, Jacob J, et al. (2008). Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer. J Clin Oncol 26: 2099–105
   PubMed Web of Science ®Google Scholar
• Katsube T, Yamano Y, Yano Y. (2008). Pharmacokinetic–pharmacodynamic modeling and simulation for in vivo bactericidal effect in murine infection model. J Pharm Sci 97:1606–14
   PubMed Web of Science ®Google Scholar
• Kobuchi S, Ito Y, Hayakawa T, et al. (2014). Semi-physiological pharmacokinetic-pharmacodynamic modeling and simulation of 5-fluorouracil for the whole time course of alterations in leukocyte, neutrophil and lymphocyte counts in rats. Xenobiotica. [Epub ahead of print]. doi: 10.3109/00498254.2014.900588
   Google Scholar
• Kobuchi S, Ito Y, Okada K, et al. (2013a). Pre-therapeutic assessment of plasma dihydrouracil/uracil ratio for predicting the pharmacokinetic parameters of 5-fluorouracil and tumor growth in a rat model of colorectal cancer. Biol Pharm Bull 36:907–16
   PubMed Web of Science ®Google Scholar
• Kobuchi S, Ito Y, Okada K, et al. (2013b). Pharmacokinetic/pharmacodynamic modeling of 5-fluorouracil by using a biomarker to predict tumor growth in a rat model of colorectal cancer. J Pharm Sci 102:2056–67
   PubMed Web of Science ®Google Scholar
• Kobuchi S, Kuwano S, Imoto K, et al. (2013c). A predictive biomarker for altered 5-fluorouracil pharmacokinetics following repeated administration in a rat model of colorectal cancer. Biopharm Drug Dispos 34:365–76
   PubMed Web of Science ®Google Scholar
• Kochi M, Akiyama Y, Aoki T, et al. (2013). FOLFIRI plus bevacizumab as a first-line treatment for Japanese patients with metastatic colorectal cancer: a JACCRO CC-03 multicenter phase II study. Cancer Chemother Pharmacol 72:1097–102
   PubMed Web of Science ®Google Scholar
• Kuwahara A, Yamamori M, Nishiguchi K, et al. (2010). Effect of dose-escalation of 5-fluorouracil on circadian variability of its pharmacokinetics in Japanese patients with Stage III/IVa esophageal squamous cell carcinoma. Int J Med Sci 7:48–54
   PubMedGoogle Scholar
• Milano G, Etienne MC, Renee N, et al. (1994). Relationship between fluorouracil systemic exposure and tumor response and patient survival. J Clin Oncol 12:1291–5
   PubMed Web of Science ®Google Scholar
• Noguchi C, Miyata H, Sato Y, et al. (2011). Evaluation of bone toxicity in various bones of aged rats. Toxicol Pathol 24:41–8
   Web of Science ®Google Scholar
• Okuma M, Yamori Y. (1976). Platelet survival studies in stroke-prone spontaneously hypertensive rats (SHRSP). Stroke 7:60–4
   Google Scholar
• Quartino AL, Friberg LE, Karlsson MO. (2012). A simultaneous analysis of the time-course of leukocytes and neutrophils following docetaxel administration using a semi-mechanistic myelosuppression model. Invest New Drugs 30:833–45
   PubMed Web of Science ®Google Scholar
• Saif MW, Choma A, Salamone SJ, et al. (2009). Pharmacokinetically guided dose adjustment of 5-fluorouracil: a rational approach to improving therapeutic outcomes. J Natl Cancer Inst 101:1543–52
   PubMed Web of Science ®Google Scholar
• Segura C, Bandrés E, Trocóniz IF, et al. (2004). Hematological response of topotecan in tumor-bearing rats: modeling of the time course of different cellular populations. Pharm Res 21:567–73
   PubMed Web of Science ®Google Scholar
• Soto E, Staab A, Tillmann C, et al. (2010). Semi-mechanistic population pharmacokinetic/pharmacodynamic model for neutropenia following therapy with the Plk-1 inhibitor BI 2536 and its application in clinical development. Cancer Chemother Pharmacol 66:785–95
   PubMed Web of Science ®Google Scholar
• Stec R, Bodnar L, Smoter M, et al. (2014). Mitomycin C and high-dose 5-fluorouracil with folinic acid as a therapeutic option for heavily pretreated patients with metastatic colorectal cancer: prospective phase II trial. Oncologist 19:356–7
   Google Scholar
• Sung JH, Dhiman A, Shuler ML. (2009). A combined pharmacokinetic-pharmacodynamic (PK-PD) model for tumor growth in the rat with UFT administration. J Pharm Sci 98:1885–904
   PubMed Web of Science ®Google Scholar
• Tamura T, Kuwahara A, Kadoyama K, et al. (2011). Effects of bolus injection of 5-fluorouracil on steady-state plasma concentrations of 5-fluorouracil in Japanese patients with advanced colorectal cancer. Int J Med Sci 8:406–12
   PubMed Web of Science ®Google Scholar
• Yoshikawa R, Kusunoki M, Yanagi H, et al. (2001). Dual antitumor effects of 5-fluorouracil on the cell cycle in colorectal carcinoma cells: a novel target mechanism concept for pharmacokinetic modulating chemotherapy. Cancer Res 61:1029–37
   PubMed Web of Science ®Google Scholar
• Zandvliet AS, Schellens JH, Dittrich C, et al. (2008). Population pharmacokinetic and pharmacodynamic analysis to support treatment optimization of combination chemotherapy with indisulam and carboplatin. Br J Clin Pharmacol 66:485–97
   PubMed Web of Science ®Google Scholar